Alerta

PHOTOACOUSTICS FOR NON-INVASIVE GLUCOSE SENSING

Resumen de: US2025295332A1

Disclosed are systems and techniques for glucose sensing. For example, an example of a process can include transmitting, by at least one transmitter into living tissue, a first signal with a first wavelength, a second signal with a second wavelength, and a third signal with a third wavelength to produce an acoustic response from the living tissue. The first wavelength has a first correlation with the blood glucose concentration, the second wavelength has a second correlation with the blood glucose concentration, and the third wavelength has a third correlation with the blood glucose concentration. The process can include receiving, by at least one receiver, a response signal of the acoustic response. The process can include determining, by at least one processor, the blood glucose concentration based on a photoacoustic spectrum of the response signal.

IMPROVED ACCURACY OF BASAL DELIVERY AMOUNTS

Resumen de: WO2025199207A1

Exemplary embodiments may attempt to account for more substantial deviations in a user's basal insulin needs and reduce or eliminate glucose level excursions that may result from such deviations more quickly than conventional insulin pump systems. The exemplary embodiments may rely upon a user's recent basal insulin delivery history to establish a current estimate of the user's basal insulin needs. Exemplary embodiments may calculate a reliability metric for a TDI value that reflects that degree of variance in TDI value for a user over a recent period, such as over multiple days or weeks. The reliability indicator may be used to adjust the TDI value that is used to establish a user's daily basal insulin needs and hourly basal insulin needs. In determining a user's basal insulin needs, the exemplary embodiments may not only look to recent basal insulin deliveries but also may account for correction boluses and/or meal boluses.

PREDICTION BASED DELIVERING OR GUIDING OF THERAPY FOR DIABETES

Resumen de: US2025299817A1

Disclosed herein are techniques for prediction based delivering or guiding of therapy for diabetes. In some embodiments, the techniques may involve predicting that a meal event is to occur. The techniques may further involve in response to predicting that the meal event is to occur, determining a partial therapy dosage to be delivered prior to the meal event occurring. The techniques may further involve determining, after a duration of time subsequent to delivery of the partial therapy dosage has elapsed, that meal consumption has not yet begun. The techniques may further involve prompting a patient to begin consumption of the meal.

METHOD FOR RECOGNIZING GLUCOSE ABNORMALITY EVENT, AND ELECTRONIC DEVICE

Resumen de: WO2025194937A1

Provided are a method for recognizing a glucose abnormality event, and an electronic device. The method for recognizing a glucose abnormality event comprises: after a first electronic device acquires glucose information of a user within a first time interval from a second electronic device, if a glucose fluctuation at a second moment relative to a third moment within the first time interval is greater than or equal to a first threshold value, the first electronic device acquiring first data; and on the basis of the first data, determining that the glucose fluctuation indicates the occurrence of a glucose abnormality event. Thus, the accuracy of recognizing a glucose abnormality event can be improved, and the interference of events such as stress and meals can be excluded without the need for asking a user wearing a CGM device about a sleep time period and/or meal time period.

DEPLOYMENT AND USE OF A CONTINUOUS ANALYTE MONITORING SYSTEM FOR IMPROVED HOME MONITORING AND READMISSION OPTIMIZATION

Resumen de: US2025299818A1

Disclosed herein are system, method, and computer program product embodiments to an improved alert and recommendation system for reducing patient readmission via the detection and treatment of patient conditions based on continuous analyte data. The disclosed techniques utilize analyte data, such as lactate, glucose, and creatinine, provided from a continuous analyte sensor to predict patient outcomes and generate recommendations for reducing patient readmission in a hospital and home setting. The disclosed system allows for early and non-invasive prediction of patient outcomes and the subsequent generation of recommended actions to facilitate patient intervention with the goal of reducing readmission of the patient.

Individualized Multiple-Day Simulation Model of Type I Diabetic Patient Decision-Making For Developing, Testing and Optimizing Insulin Therapies Driven By Glucose Sensors

Resumen de: US2025299823A1

A mathematical model of type 1 diabetes (T1D) patient decision-making can be used to simulate, in silico, realistic glucose/insulin dynamics, for several days, in a variety of subjects who take therapeutic actions (e.g. insulin dosing) driven by either self-monitoring blood glucose (SMBG) or continuous glucose monitoring (CGM). The decision-making (DM) model can simulate real-life situations and everyday patient behaviors. Accurate submodels of SMBG and CGM measurement errors are incorporated in the comprehensive DM model. The DM model accounts for common errors the patients are used to doing in their diabetes management, such as miscalculations of meal carbohydrate content, early/delayed insulin administrations and missed insulin boluses. The DM model can be used to assess in silico if/when CGM can safely substitute SMBG in T1D management, to develop and test guidelines for CGM driven insulin dosing, to optimize and individualize off-line insulin therapies and to develop and test decision support systems.

DIGITAL THERAPEUTIC METHOD AND SYSTEM EMPLOYING NUTRITIONAL COGNITIVE BEHAVIORAL THERAPY

Resumen de: US2025299799A1

Nutritional Cognitive Behavioral Therapy (Nutritional-CBT) is provided for the treatment of patients with type 2 diabetes and other cardiometabolic diseases, addressing common maladaptive thinking and beliefs pertaining to diet and lifestyle in a digitally-delivered therapy personalized to the individual patient using artificial intelligence (AI)/machine learning (ML) driven feed-back loops. Systems, methods, and computer-readable media described herein can include providing, by one or more processors, a digital therapeutic application including one or more lessons or activities. The one or more processors can collect at least one response or biometric data from the user. The one or more processors can generate, using a machine-learning model, one or more goals for the user to achieve or a progress overview.

PHOTOACOUSTICS FOR NON-INVASIVE GLUCOSE SENSING

Resumen de: WO2025198810A1

Disclosed are systems and techniques for glucose sensing. For example, an example of a process can include transmitting, by at least one transmitter into living tissue, a first signal with a first wavelength, a second signal with a second wavelength, and a third signal with a third wavelength to produce an acoustic response from the living tissue. The first wavelength has a first correlation with the blood glucose concentration, the second wavelength has a second correlation with the blood glucose concentration, and the third wavelength has a third correlation with the blood glucose concentration. The process can include receiving, by at least one receiver, a response signal of the acoustic response. The process can include determining, by at least one processor, the blood glucose concentration based on a photoacoustic spectrum of the response signal.

ACCURACY OF BASAL DELIVERY AMOUNTS

Resumen de: US2025295854A1

Exemplary embodiments may attempt to account for more substantial deviations in a user's basal insulin needs and reduce or eliminate glucose level excursions that may result from such deviations more quickly than conventional insulin pump systems. The exemplary embodiments may rely upon a user's recent basal insulin delivery history to establish a current estimate of the user's basal insulin needs. Exemplary embodiments may calculate a reliability metric for a TDI value that reflects that degree of variance in TDI value for a user over a recent period, such as over multiple days or weeks. The reliability indicator may be used to adjust the TDI value that is used to establish a user's daily basal insulin needs and hourly basal insulin needs. In determining a user's basal insulin needs, the exemplary embodiments may not only look to recent basal insulin deliveries but also may account for correction boluses and/or meal boluses.

SYSTEM AND METHODS FOR NON-RESPONSIVE SENSOR DETECTION

Resumen de: AU2024250123A1

The present disclosure relates to methods and systems for predicting glycemic events in a patient induced as a result of physical activity. In certain aspects, a method includes monitoring a plurality of analytes of the patient continuously during a time period to obtain analyte signals, the plurality of analytes including at least glucose and lactate. The method further includes processing the analyte data from the time period to determine signal-to-noise ratios of the analyte signal. The method then compares the signal-to-noise ratios to each other to determine if a sensor in the continuous analyte monitoring system is non-responsive. In alternative embodiments, a reference signal is obtained and a reference signal-to-noise ratio is compared to the analyte signal-to-noise ratio to determine if a sensor in the continuous analyte monitoring system is non-responsive.

SYSTEMS AND METHODS FOR PROCESSING AND TRANSMITTING SENSOR DATA

Resumen de: US2025295333A1

Systems and methods for processing, transmitting and displaying data received from an analyte sensor, such as a glucose sensor, are disclosed. In an embodiment, a method for transmitting data between a first communication device associated with an analyte sensor and a second communication device configured to provide user access to sensor-related information comprises: activating a transceiver of a first communication device associated with an analyte sensor at a first time; and establishing a two-way communication channel with the second communication device; wherein the activating comprises waking the transceiver from a low power sleep mode using a forced wakeup from the second communication device.

BLOOD GLUCOSE MONITORING METHOD, GRAPHICAL INTERFACE, AND RELATED APPARATUS

Resumen de: EP4620393A1

This application discloses a blood glucose monitoring method, a graphical interface, and a related apparatus. In the method, a wearable device collects a PPG signal of a user used to reflect blood glucose of the user within a time period, removes a low-quality PPG signal collected when the user is affected by an external factor, and determines, based on a reserved PPG signal, a quantity of occurrences of a blood glucose abnormality and/or a blood glucose risk of the user within the time period. It can be learned that, when data used to reflect the blood glucose of the user is collected, the user may be affected by the external factor, and the device may remove the PPG signal collected when the user is affected by the external factor. In this way, a status of the user does not need to be considered in a blood glucose monitoring process, thereby achieving an effect of unperceived blood glucose monitoring.

USER INTERFACES FOR GLUCOSE INSIGHT PRESENTATION

Resumen de: EP4620384A2

User interfaces for glucose insight presentation are leveraged. A glucose monitoring application is configured to process glucose measurements to determine one or more glucose insights, e.g., about a user's glucose. The glucose measurements, for example, may be obtained from a glucose monitoring device that collects glucose measurements of the user at predetermined intervals, e.g., every five minutes. The glucose monitoring application configures a user interface, based on configuration data, to present one or more visual elements representative of the one or more glucose insights. For example, the glucose monitoring application may configure the user interface to include a visual element in the form of a color field which represents whether the user's current glucose measurement (e.g., the most recent glucose measurement obtained from the glucose monitoring device) is below, within, or above a glucose range.

METHODS, DEVICES AND SYSTEM FOR PROVIDING DIABETIC CONDITION DIAGNOSIS AND THERAPY

Resumen de: EP4621804A2

Methods, devices and system for determining fasting glucose level information and post-prandial glucose level information for diagnosing pre-diabetic and diabetic conditions based on monitored glucose measurements are provided.

CONSTRUCTION SYSTEM FOR A CARDIOVASCULAR DISEASE RISK PREDICTION MODEL FOR PATIENTS WITH TYPE 2 DIABETES

Resumen de: LU600638B1

The present invention discloses a construction system for a cardiovascular disease risk prediction model for patients with type 2 diabetes, comprising a bottom base, a mounting slot, a prediction system, a data collection and preprocessing module, a feature selection and extraction module, a model construction module, amodel evaluation and validation module, a user interaction module, a speaker, and a display. The bottom base is provided with a mounting slot, within the mounting slot the prediction system is arranged. The present invention is designed as an integrated and comprehensive construction system for a cardiovascular disease risk prediction model for patients with type 2 diabetes. Based on the results of multifactorial Logistic regression analysis, a highly accurate risk prediction model is constructed. Furthermore, statistical methods are employed to validate the predictive performance of the model, providing a novel tool for identifying high-risk individuals for cardiovascular disease among patients with type 2 diabetes. Additionally, the present invention not only considers traditional risk factors but also incorporates biochemical indicators such as serum albumin, serum uric acid, and parathyroid hormone.

ANTIHYPERGLYCEMIC METHODS AND SYSTEMS

Resumen de: WO2025193785A1

A method of determining a dosage regimen for a glucose disorder includes receiving existing dosage information for a patient at a computing device and receiving, by the computing device, glucose data from a patient using a continuous glucose monitor. Next, the method includes determining a glycemic risk for a time period based on the glucose data, and modifying an existing basal insulin dosage when the glycemic risk indicates an elevated risk of a high glucose level in at least one time period and when the glycemic risk does not indicate an elevated risk of low glucose, and when the existing basal insulin dosage is below a predetermined maximum. Next, the method includes initiating a prandial insulin dose when the glycemic risk indicates an elevated risk of a high glucose level and when the existing basal insulin dosage is at a predetermined maximum.

METHODS AND SYSTEMS FOR MEDICATION DETERMINATION AND MANAGEMENT

Resumen de: WO2025194017A1

Systems and methods of optimizing glucose medication dosages are based on modeling a patient's glucose lowering response using historical glucose data. The model is actively updated to account for changes in the patient's medication treatments and physiological conditions based on real-time or near real-time glucose measurements from the patient. The system can analyze various dosages of insulin based on the patient's current therapy and the model to determine an optimized dosage. Also disclosed is a system and method for retrieving a patient's current medication therapies from medical records using an automated system. Also disclosed are methods of implementing remotely-updatable limitations for medication optimization algorithms.

SENSOR APPLICATOR ASSEMBLY FOR CONTINUOUS GLUCOSE MONITORING SYSTEM

Resumen de: AU2025223826A1

A sensor applicator assembly for a continuous glucose monitoring system is provided. The sensor applicator assembly is assembled as a single unitary product in which a sensor module measuring a blood glucose level is preinstalled in an applicator, such that the sensor module is ejected by an operation of the applicator to be attached to a human body. The applicator includes a main container and a plunger body fixedly coupled to a first position within the main container. The plunger body is configured to be decoupled from the first position and to be moved to a second position in an injecting direction. The sensor module is coupled to one end portion of the plunger body to be moved integrally with the plunger body as the plunger body being moved toward the second position. An adhesive layer is attached to a lower surface of the sensor module to attach the sensor module to the human body, and is configured to be moved together with the sensor module as the plunger body being moved toward the second position. A sensor applicator assembly for a continuous glucose monitoring system is provided. The sensor applicator assembly is assembled as a single unitary product in which a sensor module measuring a blood glucose level is preinstalled in an applicator, such that the sensor module is ejected by an operation of the applicator to be attached to a human body. The applicator includes a main container and a plunger body fixedly coupled to a first position within the main container. T

Analyte sensors and sensing methods for dual detection of glucose and ethanol

Resumen de: AU2025223845A1

Multiple enzymes may be present in one or more active areas of an electrochemical analyte sensor for detecting one or more different analytes. In particular, an analyte sensor may comprise a sensor tail configured for insertion into a tissue and one or more working electrodes having a glucose-responsive active area and an ethanol- responsive active area to detect glucose and ethanol in vivo. Multiple enzymes may be present in one or more active areas of an electrochemical analyte sensor for detecting one or more different analytes. In particular, an analyte sensor may comprise a sensor tail configured for insertion into a tissue and one or more working electrodes having a glucose-responsive active area and an ethanol- responsive active area to detect glucose and ethanol in vivo. ug u l t i p l e e n z y m e s m a y b e p r e s e n t i n o n e o r m o r e a c t i v e a r e a s o f a n e l e c t r o c h e m i c a l u g a n a l y t e s e n s o r f o r d e t e c t i n g o n e o r m o r e d i f f e r e n t a n a l y t e s n p a r t i c u l a r , a n a n a l y t e s e n s o r m a y c o m p r i s e a s e n s o r t a i l c o n f i g u r e d f o r i n s e r t i o n i n t o a t i s s u e a n d o n e o r m o r e w o r k i n g e l e c t r o d e s h a v i n g a g l u c o s e - r e s p o n s i v e a c t i v e a r e a a n d a n e t h a n o l - r e s p o n s i v e a c t i v e a r e a t o d e t e c t g l u c o s e a n d e t h a n o l i n v i v o

METHODS AND SYSTEMS FOR MEDICATION DETERMINATION AND MANAGEMENT

Resumen de: US2025288224A1

Systems and methods of optimizing glucose medication dosages are based on modeling a patient's glucose lowering response using historical glucose data. The model is actively updated to account for changes in the patient's medication treatments and physiological conditions based on real-time or near real-time glucose measurements from the patient. The system can analyze various dosages of insulin based on the patient's current therapy and the model to determine an optimized dosage. Also disclosed is a system and method for retrieving a patient's current medication therapies from medical records using an automated system. Also disclosed are methods of implementing remotely-updatable limitations for medication optimization algorithms.

NON-INVASIVE CONTINUOUS BLOOD GLUCOSE CONCENTRATION (BGC) MEASUREMENT METHOD AND APPARATUS BASED ON OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY (OCTA)

Resumen de: US2025288225A1

A non-invasive continuous blood glucose concentration (BGC) measurement method and apparatus based on optical coherence tomography angiography (OCTA) are provided. The method includes: performing continuous OCT scanning and imaging on a target tissue region; extracting, based on a depth attenuation characteristic of an OCT signal, a three-dimensional optical scattering coefficient of the target tissue region; generating a three-dimensional microvascular distribution of the target tissue region; accurately distinguishing a blood optical scattering coefficient (BOC) from a tissue optical scattering coefficient (TOC) based on the three-dimensional scattering coefficient and the three-dimensional microvascular distribution; and measuring reference BGCs at two time points through an electrochemical method; and combining the reference BGCs with the BOC and the TOC respectively, thereby achieving continuous measurement of a BGC and an interstitial fluid glucose concentration (IGC). The method and apparatus are based on OCTA to achieve accurate BGC measurement while simultaneously enabling IGC measurement.

METHOD AND APPARATUS FOR IMPROVING LAG CORRECTION DURING IN VIVO MEASUREMENT OF ANALYTE CONCENTRATION WITH ANALYTE CONCENTRATION VARIABILITY AND RANGE DATA

Resumen de: US2025288226A1

Methods, devices, and systems are provided. A method includes receiving sensor data from the glucose sensor, the sensor data being associated with a time window, determining a rate of change distribution of the sensor data, determining a first slope that corresponds to a line of the rate of change distribution, comparing a first slope with a first reference slope, generating, based on comparing the first slope with the first reference slope, an output; and, transmitting the output to a display or a transmitter. Numerous additional features are disclosed.

SYSTEMS AND METHODS FOR SMART BIAS VOLTAGE FOR INSULIN INTERFERENCE COMPENSATION

Resumen de: US2025288228A1

An analyte sensor configured to compensate for insulin interference includes: a working electrode, including an analyte sensing molecule disposed on the working electrode configured to generate a signal when exposed to an analyte; a processor; and a memory. The memory includes instructions which, when executed by the processor, cause the sensor to: obtain an indication from the pump that the bolus is delivered; in response to the delivery of the bolus, determine at least one of a first electrochemical impedance spectroscopy (EIS) parameter value or a first conductivity value in response to exposure of the working electrode to the analyte; and determine a presence of one or more interferents based on at least one of the first EIS parameter value or the first conductivity value.

METHODS, SYSTEMS, AND DEVICES FOR DETERMINING GLUCOSE MEASUREMENTS

Resumen de: WO2025189236A1

Some embodiments relate to devices and methods for determining a measure of glucose in a first substance. An example device may comprise: a light source configured to emit near-infrared light at a first wavelength at a first quantity of the first substance, the first substance comprising a second substance and glucose; a detector, configured to: detect light from the first substance; and provide a signal indicative of an intensity of the detected light; and a controller, configured to: receive the signal from the detector; determine a first measure indicative of the intensity of the detected light from the first substance; determine a measure of glucose in the first substance as a difference between the first measure and a second measure, wherein the second measure is indicative of the intensity of detected light from a second quantity of the second substance when subjected to near-infrared light at the first wavelength; and provide an output based on the determined measure of glucose.

CONTINUOUS BLOOD SUGAR MEASURING DEVICE

Nº publicación: ES3036439T3 18/09/2025

Solicitante:

I SENS INC
i-Sens, Inc

Resumen de: US2024306955A1

The present disclosure relates to a continuous blood sugar measuring device, and provides a continuous blood sugar measuring device which is capable of minimizing additional work of a user in order to attach a body attachment unit, by manufacturing the body attachment unit to be assembled inside an applicator so that the body attachment unit can be attached to the body simply by operating the applicator and, particularly: communicating with an external terminal by providing a wireless communication chip in the body attachment unit so that simple and convenient use is possible and maintenance can easily be performed without the additional work of connecting a separate transmitter; initiating operation by a manipulation of the user, after attaching the body attachment unit to the body, so that an operation initiation time can be adjusted to a suitable time according to the need of the user; and initiating operation in a stabilized state to enable a more accurate measurement of blood sugar.